Andy Perlman

Andrew J. Perlman MD, PhD is the Co-Founder and Head of Pre-Clinical Science at X-37, an AI enabled drug discovery company, as well as Co-Founder and Chief Medical Officer at Velocity Pharmaceutical Development.

Previously, he was Executive VP at Tularik Inc., Senior Director of Clinical Research at Genentech, CEO and co-founder of Innate Immune Inc, and CEO of Affytmax. He holds a BS degree in physics from MIT and an MD and PhD from NYU.